These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 14600527)

  • 21. [Poly-L-lactic-acid filling of facial lipoatrophy in HIV+ patients under tritherapy].
    Thiéry G; Coulet O; Adam S; Guyot L
    Rev Stomatol Chir Maxillofac; 2008 Apr; 109(2):103-5. PubMed ID: 18374957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of polylactic acid in face lipodystrophy in HIV positive patients undergoing treatment with antiretroviral drugs (HAART).
    Onesti MG; Renzi LF; Paoletti F; Scuderi N
    Acta Chir Plast; 2004; 46(1):12-5. PubMed ID: 15274472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy.
    Moyle GJ; Brown S; Lysakova L; Barton SE
    HIV Med; 2006 Apr; 7(3):181-5. PubMed ID: 16494632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Poly-L-lactic acid for facial lipoatrophy in HIV.
    El-Beyrouty C; Huang V; Darnold CJ; Clay PG
    Ann Pharmacother; 2006 Sep; 40(9):1602-6. PubMed ID: 16912248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience.
    Mest DR; Humble G
    Dermatol Surg; 2006 Nov; 32(11):1336-45. PubMed ID: 17083585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Semipermanent filler treatment of HIV-positive patients with facial lipoatrophy: long-term follow-up evaluating MR imaging and quality of life.
    van Rozelaar L; Kadouch JA; Duyndam DA; Nieuwkerk PT; Lutgendorff F; Karim RB
    Aesthet Surg J; 2014 Jan; 34(1):118-32. PubMed ID: 24334306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up.
    Carey D; Baker D; Petoumenos K; Chuah J; Rogers GD; Watson J; Cooper DA; Emery S; Carr A;
    HIV Med; 2009 Mar; 10(3):163-72. PubMed ID: 19245538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biodegradable polymers for ocular drug delivery.
    Kimura H; Ogura Y
    Ophthalmologica; 2001; 215(3):143-55. PubMed ID: 11340382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polylactic acid vs. polyacrylamide hydrogel for treatment of facial lipoatrophy: a randomized controlled trial [Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 132 SMILE].
    Lafaurie M; Dolivo M; Girard PM; May T; Bouchaud O; Carbonnel E; Madelaine I; Loze B; Porcher R; Molina JM;
    HIV Med; 2013 Aug; 14(7):410-20. PubMed ID: 23432777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Injectable poly-L-lactic acid (Sculptra): technical considerations in soft-tissue contouring.
    Lam SM; Azizzadeh B; Graivier M
    Plast Reconstr Surg; 2006 Sep; 118(3 Suppl):55S-63S. PubMed ID: 16936545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Use of Poly-L-Lactic Acid in the Gluteal Area.
    Mazzuco R; Sadick NS
    Dermatol Surg; 2016 Mar; 42(3):441-3. PubMed ID: 26859651
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging.
    Hanke CW; Redbord KP
    J Drugs Dermatol; 2007 Feb; 6(2):123-8. PubMed ID: 17373169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The evolution of injectable poly-L-lactic acid from the correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies.
    Burgess C
    J Drugs Dermatol; 2011 Sep; 10(9):1001-6. PubMed ID: 22052268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The "smile-and-fill" injection technique: a dynamic approach to midface volumization.
    Wang AS; Babalola O; Jagdeo J
    J Drugs Dermatol; 2014 Mar; 13(3):288-90. PubMed ID: 24595573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [L-polylactic acid].
    Taéron C
    Rev Infirm; 2005 Dec; (116):35-6. PubMed ID: 16454008
    [No Abstract]   [Full Text] [Related]  

  • 36. Discussion: Autologous fat grafting and injectable dermal fillers for human immunodeficiency virus-associated facial lipodystrophy: a comparison of safety, efficacy, and long-term treatment outcomes.
    Teplica D
    Plast Reconstr Surg; 2013 Mar; 131(3):507-509. PubMed ID: 23446564
    [No Abstract]   [Full Text] [Related]  

  • 37. Poly-L-lactic acid: an overview.
    Simamora P; Chern W
    J Drugs Dermatol; 2006 May; 5(5):436-40. PubMed ID: 16703779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Late-onset, recurrent facial nodules associated with injection of poly-L-lactic acid.
    Hamilton DG; Gauthier N; Robertson BF
    Dermatol Surg; 2008 Jan; 34(1):123-6; discussion 126. PubMed ID: 18053031
    [No Abstract]   [Full Text] [Related]  

  • 39. Lexicon for soft tissue implants.
    Rohrich RJ; Nguyen AT; Kenkel JM
    Dermatol Surg; 2009 Oct; 35 Suppl 2():1605-11. PubMed ID: 19807754
    [No Abstract]   [Full Text] [Related]  

  • 40. A systematic review of filler agents for aesthetic treatment of HIV facial lipoatrophy (FLA).
    Jagdeo J; Ho D; Lo A; Carruthers A
    J Am Acad Dermatol; 2015 Dec; 73(6):1040-54.e14. PubMed ID: 26481056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.